Gilead makes physical drugs for biological diseases that AGI cannot cure through software — low disruption risk with potential AGI upside in accelerated drug discovery.
Gilead Sciences is a biopharmaceutical company focused on developing and commercializing innovative medicines in areas of unmet medical need, primarily HIV/AIDS, liver diseases (hepatitis B and C), oncology/hematology, and inflammation. The company is the global leader in HIV treatment and prevention, with its antiretroviral therapies used by millions of patients worldwide. Gilead also developed the blockbuster hepatitis C cures (Sovaldi/Harvoni) and Veklury (remdesivir) for COVID-19. Through its acquisition of Kite Pharma, Gilead is a leader in CAR-T cell therapy for cancer.
Healthcare providers (hospitals, clinics, infectious disease specialists, oncologists), wholesalers and specialty pharmacy distributors, government health agencies (Ryan White program, VA, international programs like PEPFAR), and patients. Gilead sells through major pharmaceutical distributors including McKesson, AmerisourceBergen, and Cardinal Health in the US.
AGI cannot replace pharmaceutical drugs. Gilead's products — HIV antivirals (Biktarvy, Descovy), hepatitis C cures (Sovaldi, Harvoni), oncology cell therapies (Yescarta, Tecartus), and pulmonary drugs — are physical molecules and biological therapies that must be manufactured, distributed, and administered to patients. AGI could accelerate drug discovery (potentially for competitors), but the drugs themselves are physical products protected by patents and regulatory exclusivity. Gilead's customers are patients, hospitals, and healthcare systems. People with HIV, cancer, and liver disease will continue to need treatment regardless of AGI. Disease does not care about technological disruption.